G Yothers
Overview
Explore the profile of G Yothers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen R, Raeisi M, Chibaudel B, Yothers G, Goldberg R, Bachet J, et al.
ESMO Open
. 2025 Mar;
10(3):104481.
PMID: 40043353
Background: Standard adjuvant treatment of stage III colon cancer (CC) is fluoropyrimidine with oxaliplatin. Recently, stage III was subdivided into low-risk (T1-3, N1) and high-risk (T4 and/or N2), with the...
2.
Alvarez J, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George T, et al.
medRxiv
. 2024 May;
PMID: 38712176
Background: Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to...
3.
Taieb J, Sinicrope F, Pederson L, Lonardi S, Alberts S, George T, et al.
Ann Oncol
. 2023 Aug;
34(11):1025-1034.
PMID: 37619846
Background: The prognostic value of KRAS and BRAF mutations in stage III colon cancer (CC) remains controversial and has never been clearly analyzed in patients with microsatellite instability-high (MSI-H) tumors...
4.
Geyer Jr C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al.
Ann Oncol
. 2022 Oct;
33(12):1250-1268.
PMID: 36228963
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic...
5.
Salem M, Yin J, Goldberg R, Pederson L, Wolmark N, Alberts S, et al.
Ann Oncol
. 2020 Feb;
31(4):480-486.
PMID: 32085892
Background: Since 2004, adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX or FLOX) have been the standard of care for patients with resected colon cancer. Herein we examine the change of outcomes...
6.
Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, et al.
Ann Oncol
. 2019 Jul;
30(9):1466-1471.
PMID: 31268130
Background: Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAFV600E complicates the association. Patients And Methods: Patients...
7.
Renfro L, Grothey A, Kerr D, Haller D, Andre T, Van Cutsem E, et al.
Ann Oncol
. 2015 Feb;
26(5):950-958.
PMID: 25697217
Background: Post-treatment survival experience of early colon cancer (CC) patients is well described in the literature, which states that cure is probable for some patients. However, comparisons of treated patients'...
8.
Haller D, Oconnell M, Cartwright T, Twelves C, McKenna E, Sun W, et al.
Ann Oncol
. 2015 Jan;
26(4):715-724.
PMID: 25595934
Background: Adjuvant oxaliplatin plus capecitabine or leucovorin/5-fluorouracil (LV/5-FU) (XELOX/FOLFOX) is the standard of care for stage III colon cancer (CC); however, there is disagreement regarding oxaliplatin benefit in patients aged...
9.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, et al.
Eur J Cancer
. 2011 Jan;
47(7):990-6.
PMID: 21257306
Background: The ACCENT group previously established disease-free survival (DFS) with 2 or 3 years median follow-up to predict 5 year overall survival (5 year OS) in stage II and III...
10.
Green E, Yothers G, Sargent D
Stat Methods Med Res
. 2008 Feb;
17(5):477-86.
PMID: 18285438
A variety of approaches have been proposed to provide formal and informal validation of proposed surrogate markers. To achieve true clinical impact, the validation must convince both the statistical and...